Arterial hypertension remains the leading contributor to global morbidity and mortality, yet only a minority of patients achieve adequate blood pressure (BP) control [1]. This persistent gap is likely driven by multiple converging factors, including suboptimal medication adherence, therapeutic inertia among healthcare providers, and difficulties in effectively targeting pathways known to drive persistent BP elevation. A paradigmatic example is the overactivation of aldosterone secretion, now recognised as a central pathophysiological mechanism sustaining BP elevation in patients with resistant hypertension (rHTN) [2].
